The 2019 AACE guidelines (34) recommend using a GH cut-point of 3 μg/L for normal-weight patients (BMI <25 kg/m2), a GH cut-point of 1 μg/L in patients with obesity (BMI >30 kg/m2), and a GH cut-point of 3 or 1 μg/L in overweight patients (BMI 25-30 kg/m2) based on the high or low pretest probability. This evidence concerns the gene GH1 and obesity disorder.